Home LiteratureArticle Details
PMID: 33301605 Published · ppublish English Journal Article

The long noncoding RNA DLGAP1-AS2 facilitates cholangiocarcinoma progression via miR-505 and GALNT10.

FEBS open bio ·Vol. 11 ·No. 2 ·2021-00-00 ·Pages 413-422

Liu Z, Pan L, Yan X, Duan X

Abstract

Cholangiocarcinoma (CCA) is a highly invasive malignant tumor with high mortality. Most cases of CCA are already advanced when they are detected, resulting in poor prognosis. As such, there is an ongoing need for the identification of effective biomarkers for CCA. The long noncoding RNA DLGAP1-AS2 has been reported to have prognostic value in glioma and Wilms' tumor. Here, we investigated the function of DLGAP1-AS2 in CCA. The differential expression of DLGAP1-AS2 in CCA tissues and normal tissues was first examined using data from the The Cancer Genome Atlas database and then in CCA cell lines by quantitative RT-PCR (qRT-PCR). The target gene was predicted by bioinformatics analysis, and the binding sites were confirmed using luciferase assay. DLGAP1-AS2 is up-regulated in CCA, and high DLGAP1-AS2 expression promotes cell viability and is associated with poor prognosis. Notably, DLGAP1-AS2 acts as a sponge to suppress miR-505 expression, and miR-505 reduces the expression of N-acetylgalactosaminyltransferase 10 (GALNT10) in CCA cells. Biofunctional experiments revealed that a miR-505 inhibitor almost completely removed the inhibitory effect of si-DLGAP1-AS2 on CCA cell malignant progression, whereas the malignant phenotype of cells cotransfected with si-DLGAP1-AS2 and si-GALNT10 was significantly reduced as compared with the control. In summary, the DLGAP1-AS2/miR-505/GALNT10 axis may contribute to regulating the malignant progression of CCA and may have potential as a novel target for CCA therapy.

Keywords
DLGAP1-AS2 GALNT10 cholangiocarcinoma miR-505 migration viability
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Liu Zhao
Department of Hepatobiliary and Pancreatic Surgery, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Pan Lili
Department of Hepatobiliary and Pancreatic Surgery, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Yan Xiaofang
Department of Nuclear Medicine, Central Hospital of Shan County, Heze, China.
Duan Xiuna ORCID
Department of Nuclear Medicine, Central Hospital of Shan County, Heze, China.
References (31)
31 references, click to expand
  1. Razumilava N and Gores GJ (2014) Cholangiocarcinoma. Lancet 383, 2168-2179.
  2. Chiang NJ, Shan YS, Hung W-C and Chen L-T (2015) Epigenetic regulation in the carcinogenesis of cholangiocarcinoma. Int J Biochem Cell Biol 67, 110-114.
  3. Rizvi S, Khan SA, Hallemeier CL, Kelley RK and Gores GJ (2018) Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 15, 95-111.
  4. Khan SA, Toledano MB and Taylor-Robinson SD (2008) Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB 10, 77-82.
  5. Doherty B, Nambudiri VE and Palmer WC (2017) Update on the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep 19, 2.
  6. Dykes IM and Emanueli C (2017) Transcriptional and post-transcriptional gene regulation by long non-coding RNA. Genom Proteomics Bioinformatics 15, 177-186.
  7. Quinn JJ and Chang HY (2016) Unique features of long non-coding RNA biogenesis and function. Nat Rev Genet 17, 47-62.
  8. Ransohoff JD, Wei Y and Khavari PA (2018) The functions and unique features of long intergenic non-coding RNA. Nat Rev Mol Cell Biol 19, 143-157.
  9. Sanchez Calle A, Kawamura Y, Yamamoto Y, Takeshita F and Ochiya T (2018) Emerging roles of long non-coding RNA in cancer. Cancer Sci 109, 2093-2100.
  10. Chi Y, Wang D, Wang J, Yu W and Yang J (2019) Long non-coding RNA in the pathogenesis of cancers. Cells 8, 1015.
  11. Li Y, Cai Q, Li W, Feng F and Yang L (2018) Long non-coding RNA EPIC1 promotes cholangiocarcinoma cell growth. Biochem Biophys Res Commun 504, 654-659.
  12. Tang L, Wang Y, Wang H, Xu B, Ji H, Xu G, Ge X, Li Q and Miao L (2019) Long noncoding-RNA component of mitochondrial RNA processing endoribonuclease is involved in the progression of cholangiocarcinoma by regulating microRNA-217. Cancer Sci 110, 2166-2179.
  13. Miao W, Li N, Gu B, Yi G, Su Z and Cheng H (2020) LncRNA DLGAP1-AS2 modulates glioma development by up-regulating YAP1 expression. J Biochem 167, 411-418.
  14. Ren P and Hu M (2019) A three long non-coding RNA signature to improve survival prediction in patients with Wilms' tumor. Oncol Lett 18, 6164-6170.
  15. Zhao L, Zhang X, Guo H, Liu M and Wang L (2020) LOXL1-AS1 contributes to non-small cell lung cancer progression by regulating miR-3128/RHOXF2 Axis. Onco Targets Ther 13, 6063-6071.
  16. Zeng M, Zhu L, Li L and Kang C (2017) miR-378 suppresses the proliferation, migration and invasion of colon cancer cells by inhibiting SDAD1. Cell Mol Biol Lett 22, 12.
  17. Zhen S, Hua L, Liu YH, Sun XM, Jiang MM, Chen W, Zhao L and Li X (2017) Inhibition of long non-coding RNA UCA1 by CRISPR/Cas9 attenuated malignant phenotypes of bladder cancer. Oncotarget 8, 9634-9646.
  18. Bhan A, Soleimani M and Mandal SS (2017) Long noncoding RNA and cancer: a new paradigm. Cancer Res 77, 3965-3981.
  19. Liu Y, Yang Y, Li L, Liu Y, Geng P, Li G and Song H (2018) LncRNA SNHG1 enhances cell proliferation, migration, and invasion in cervical cancer. Biochem Cell Biol 96, 38-43.
  20. Jiang N, Meng X, Mi H, Chi Y, Li S, Jin Z, Tian H, He J, Shen W, Tian H et al. (2018) Circulating lncRNA XLOC_009167 serves as a diagnostic biomarker to predict lung cancer. Clin Chim Acta 486, 26-33.
  21. Zhang YX, Yuan J, Gao ZM and Zhang ZG (2018) LncRNA TUC338 promotes invasion of lung cancer by activating MAPK pathway. Eur Rev Med Pharmacol Sci 22, 443-449.
  22. Wang LJ, He CC, Sui X, Cai MJ, Zhou CY, Ma JL, Wu L, Wang H, Han SX and Zhu Q (2015) MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN. Oncotarget 6, 5932-5946.
  23. Zhang M, Shi B and Zhang K (2019) miR-186 suppresses the progression of cholangiocarcinoma cells through inhibition of Twist1. Oncol Res 27, 1061-1068.
  24. Chen Y, Bian L and Zhang Y (2018) MiR-505 mediates methotrexate resistance in colorectal cancer by targeting RASSF8. J Pharm Pharmacol 70, 937-951.
  25. Tian L, Wang ZY, Hao J and Zhang XY (2018) miR-505 acts as a tumor suppressor in gastric cancer progression through targeting HMGB1. J Cell Biochem 120, 8044-8052.
  26. Chen S, Sun KX, Liu BL, Zong ZH and Zhao Y (2016) MicroRNA-505 functions as a tumor suppressor in endometrial cancer by targeting TGF-α. Mol Cancer 15, 11.
  27. Liu YJ, Li W, Chang F, Liu JN, Lin JX and Chen DX (2018) MicroRNA-505 is downregulated in human osteosarcoma and regulates cell proliferation, migration and invasion. Oncol Rep 39, 491-500.
  28. Ren L, Yao Y, Wang Y and Wang S (2019) MiR-505 suppressed the growth of hepatocellular carcinoma cells via targeting IGF-1R. Biosci Rep 39, BSR20182442.
  29. Liu L, Xiong Y, Xi W, Wang J, Qu Y, Lin Z, Chen X, Yao J, Xu J and Guo J (2017) Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma. Oncotarget 8, 14995-15003.
  30. Zhang G, Lu J, Yang M, Wang Y, Liu H and Xu C (2020) Elevated GALNT10 expression identifies immunosuppressive microenvironment and dismal prognosis of patients with high grade serous ovarian cancer. Cancer Immunol Immunother 69, 175-187.
  31. Wu Q, Liu HO, Liu YD, Liu WS, Pan D, Zhang WJ, Yang L, Fu Q, Xu J-J and Gu J-X (2015) Decreased expression of hepatocyte nuclear factor 4α (Hnf4α)/microRNA-122 (miR-122) axis in hepatitis B virus-associated hepatocellular carcinoma enhances potential oncogenic GALNT10 protein activity. J Biol Chem 290, 1170-1185.
Full Text / Full Text
PMC full text available locally, click to read

Loading full text...

Article Info
Journal
FEBS open bio
Abbr.
FEBS Open Bio
ISSN
2211-5463
DOI
10.1002/2211-5463.13061
Published
2021-00-00
Epub
2020-00-31
Pages
413-422
Language
English
Region
England
NLM ID
101580716
PMCID
PMC7876506
Subset
IM
External Links
PubMed source DOI: 10.1002/2211-5463.13061 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2